WO2022175752 - TYK2 INHIBITORS AND USES THEREOF

National phase entry:
Publication Number WO/2022/175752
Publication Date 25.08.2022
International Application No. PCT/IB2022/000086
International Filing Date 16.02.2022
Title **
[English] TYK2 INHIBITORS AND USES THEREOF
[French] INHIBITEURS DE TYK2 ET LEURS UTILISATIONS
Applicants **
SUDO BIOSCIENCES LIMITED
Inventors
PANDEY, Anjali
DIETSCH, Gregory
CHAUDHURI, Bhaskar
MANOJVEER, Seetharaman
THAKKAR, Mahesh
DURAISWAMY, Athisayamani, Jeyaraj
KALVA, Sukesh
Priority Data
63/151,287   19.02.2021   US
63/193,511   26.05.2021   US
63/234,934   19.08.2021   US
63/291,222   17.12.2021   US
Application details
Total Number of Claims/PCT *
Number of Independent Claims *
Number of Priorities *
Number of Multi-Dependent Claims *
Number of Drawings *
Pages for Publication *
Number of Pages with Drawings *
Pages of Specification *
*
Number of Office Actions *
*
International Searching Authority
*
Recordal of a Change of the Applicant's Name/Address
*
Type of Assignment
*
Applicant's Legal Status
*
*
*
*
*
*
Entry into National Phase under
*
Patent Delivery
*
Translation

* The data is based on automatic recognition. Please verify and amend if necessary.

** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.

Quotation for National Phase entry

Country StagesTotal
China Filing, Examination, Granting5628
EPO Filing, Examination, Granting82644
Japan Filing, Examination, Granting4553
South Korea Filing, Examination, Granting6647
USA Filing, Examination, Granting33040
MasterCard Visa
Total: 132,512

The term for entry into the National Phase has expired. This quotation is for informational purposes only

Contact Us
Abstract[English] Described herein are compounds that are TYK2 inhibitors, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders that would benefit from modulation of TYK2 activity.[French] L'invention concerne des composés qui sont des inhibiteurs de TYK2, des procédés de fabrication de tels composés, des compositions pharmaceutiques et des médicaments comprenant de tels composés et des procédés d'utilisation de tels composés dans le traitement d'états pathologiques, de maladies ou de troubles qui pourraient bénéficier de la modulation de l'activité de TYK2.

Rejoining the server...